Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama reduced its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 16.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 333,287 shares of the company’s stock after selling 67,962 shares during the period. Retirement Systems of Alabama’s holdings in Teva Pharmaceutical Industries were worth $6,732,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Advisors Asset Management Inc. acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $41,000. Cromwell Holdings LLC grew its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares during the last quarter. MAI Capital Management lifted its position in Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after buying an additional 697 shares in the last quarter. Finally, JTC Employer Solutions Trustee Ltd acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $65,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director owned 367,600 shares in the company, valued at approximately $11,116,224. The trade was a 17.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 622,060 shares of company stock valued at $17,076,965. Corporate insiders own 0.49% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — EPS $0.96 vs. $0.65 consensus and revenue $4.71B vs. $4.36B; management highlighted branded-drug strength (notably Austedo) and a Sanofi milestone that lifted the quarter. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Fourth-quarter profit/revenue rise story notes the milestone payment that kicked off a late?stage IBD study and helped drive results — supports the case for durable branded-product growth. Teva Pharmaceutical profit, revenue rise in fourth quarter
• Positive Sentiment: Analysts raised targets: Truist bumped its target to $38 (buy) and Scotiabank to $40 (sector outperform), signaling dealer confidence in upside from the beat and pipeline progress. Benzinga TickerReport — Scotiabank target raise
• Positive Sentiment: Company highlights 3rd consecutive year of growth (2025 revenues $17.3B) and positions its pipeline as value?creating, which supports a longer?term growth narrative beyond near?term guidance. GlobeNewswire — Teva delivers 3 consecutive years of growth
• Neutral Sentiment: Company released the earnings slide deck and hosted an earnings call — useful for investors wanting details on segment trends, pipeline timelines and margin assumptions. MarketBeat — Earnings materials
• Neutral Sentiment: Seeking Alpha published the Q4 earnings call transcript and the results presentation for investors who want full management commentary and Q&A. SA — Earnings call transcript SA — Presentation
• Neutral Sentiment: PR/awareness activity (Will Forte campaign about Huntington’s disease) may raise public awareness but is unlikely to move near?term fundamentals materially. Yahoo Finance — Will Forte Teams Up with Teva
• Negative Sentiment: FY?2026 guidance is cautious on revenue: EPS guidance of 2.57–2.77 is roughly in line with consensus, but the revenue range of $16.4–16.8B sits below the ~$17.0B street estimate — investors may view this as a near?term headwind despite the quarter’s beat.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Barclays started coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target for the company. Finally, Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $35.67.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $33.04 on Friday. The firm has a 50-day simple moving average of $30.29 and a two-hundred day simple moving average of $23.03. The stock has a market cap of $37.90 billion, a PE ratio of 27.54, a P/E/G ratio of 1.89 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $33.44. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter last year, the company posted $0.71 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.